Want to see NBTX full AI Analyst Report?
NBTX Stock Chart & Stats
$41.51
$0.48(1.21%)
At close: 4:00 PM EDT
$41.51
$0.48(1.21%)
Day’s Range― - ―
52-Week Range$10.58 - $57.14
Previous Close$40.18
Volume95.22K
Average Volume (3M)158.28K
Market Cap
$1.77B
Enterprise Value$1.17K
Total Cash (Recent Filing)$52.75M
Total Debt (Recent Filing)$95.32M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Sep 30, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding50,619,583
10 Day Avg. Volume118,262
30 Day Avg. Volume158,279
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$64.00Price Target Upside54.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$24.36M
Bulls Say, Bears Say
Bulls Say
Nanomedicine PlatformNanobiotix’s locally administered nanoparticle approach is designed to enhance radiotherapy and potentially other treatment modalities. A differentiated platform may support multiple oncology applications and create partnering value as clinical evidence develops over the next several quarters.
Strategic Partnership ModelThe Janssen collaboration provides a route to funded development and potential milestone, royalty, or profit-sharing economics without requiring Nanobiotix to build a broad commercial infrastructure alone. This can improve strategic reach if NBTXR3 advances through development.
Intellectual Property And Market AccessA broad patent portfolio and listings on Euronext Paris and Nasdaq support protection of the technology and access to international stakeholders. These structural assets may help Nanobiotix attract capital and partners while advancing its late-stage clinical pipeline.
Bears Say
Persistent UnprofitabilityDespite the 2025 revenue rebound, recurring operating and net losses remain, with a deeply negative 2025 net margin. The company has not demonstrated sustainable profitability, so future progress still depends on clinical and commercial execution rather than an established earnings base.
Persistent Cash BurnOperating and free cash flow were negative every year provided, including approximately -$33.4M and -$34.0M in 2025. Persistent cash burn means operations require external funding, reducing financial resilience and potentially limiting clinical development flexibility.
Weak CapitalizationNegative stockholders’ equity in 2022–2025 and debt of about $95.3M versus $67.8M of assets indicate weakened capitalization and elevated leverage. This reduces financial flexibility and makes future funding more consequential while the company remains clinical-stage.
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $10.58 and its highest was $57.14 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is $1.77B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Sep 30, 2026 which is in 11 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Mar 31, 2026. The company reported -$0.453 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $0.054.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -0.29.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 50,619,583 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -$0.453 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -6.58%.
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in NBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.00 (54.18% Upside)
$64.00 (54.18% Upside)
Blogger Sentiment
Bullish
NBTX Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 105.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 12.8%
Last 30 Days ▼ 12.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Learn more about TipRanks Smart Score
Company Description
Nanobiotix
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
NBTX Stock 12 Month Forecast
Average Price Target
$64.00
▲(54.18% Upside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
11.11% Other Institutional Investors
88.87% Public Companies and
Individual Investors